Vergoeding 2019-2023 voor ATC-subgroep L04AC : Interleukineremmers
- Raming voor de totale Zvw-populatie
| 2019 | 2020 | 2021 | 2022* | 2023* | |
|---|---|---|---|---|---|
| L04AC03 Anakinra | 3.446.944 | 4.012.922 | 4.023.770 | 4.328.602 | 4.681.129 |
| L04AC05 Ustekinumab | 61.661.560 | 72.573.609 | 88.797.715 | 105.001.133 | 134.670.399 |
| L04AC07 Tocilizumab | 28.370.910 | 28.445.914 | 37.700.815 | 30.819.465 | 35.966.370 |
| L04AC08 Canakinumab | 18.096.527 | 22.698.685 | 26.598.065 | 28.812.921 | 31.779.802 |
| L04AC10 Secukinumab | 23.290.372 | 24.456.853 | 29.600.525 | 31.269.439 | 34.246.798 |
| L04AC11 Siltuximab | 66.054 | 42.935 | 71.986 | 98.112 | 153.006 |
| L04AC12 Brodalumab | 803.222 | 949.513 | 2.849.732 | 2.480.600 | 2.315.367 |
| L04AC13 Ixekizumab | 7.523.600 | 9.248.031 | 10.318.522 | 12.109.323 | 15.470.267 |
| L04AC14 Sarilumab | 1.619.684 | 2.555.961 | 5.109.864 | 3.664.202 | 3.263.378 |
| L04AC16 Guselkumab | 5.871.835 | 7.967.544 | 10.252.580 | 12.821.411 | 16.077.555 |
| L04AC17 Tildrakizumab | . | 657.342 | 1.886.673 | 1.680.063 | 1.277.583 |
| L04AC18 Risankizumab | 326.835 | 2.065.251 | 4.741.838 | 7.252.786 | 9.668.655 |
| L04AC19 Satralizumab | . | . | . | . | 13.771 |
| L04AC21 Bimekizumab | . | . | 63.239 | 948.160 | 1.917.418 |
| L04AC22 Spesolimab | . | . | . | . | 17.985 |
| Totaal | 151.077.543 | 175.674.561 | 222.015.325 | 241.286.218 | 291.519.482 |